5T4-Targeted Immunotherapy Candidates Pipeline Review

Target: 5T4; Trophoblast Glycoprotein; TPBG

Product Category: Antibody; Vaccine

This product provides basic information on immunotherapy candidates in research and development targeting 5T4.

This product consists of:

• Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
• Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
• One-month online access to La Merie Publishing’s database for immunotherapy candidates targeting 5T4 (prerequisite: access to internet).

This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.

Cell-surface protein Trophoblast glycoprotein (TPBG) 5T4 is a highly expressed tumor-associated antigen associated with adverse clinical outcomes in solid tumors, and is an attractive therapeutic target due to low expression on normal adult tissues. 5T4 is a protein expressed on cancer cells and stromal cells that support tumor growth associated with poor prognosis in several cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, breast cancer, and head and neck squamous cell carcinomas (HNSCC). While several therapeutic agents targeting 5T4 antigen are currently being evaluated in human clinical trials, none have yet entered the market.